Legal & General Group
CRVS icon

Legal & General Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Legal & General Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.1K Sell
5,678
-109
-2% -$1.74K ﹤0.01% 2626
2025
Q4 		$44.6K Sell
5,787
-737
-11% -$5.81K ﹤0.01% 2758
2025
Q3 		$48.1K Buy
6,524
+691
+12% +$3.54K ﹤0.01% 2742
2025
Q2 		$23.3K Buy
+5,833
New +$21.2K ﹤0.01% 2946
2019
Q3 		– Sell
-2,059
Closed -$7K – 3367
2019
Q2 		$7K Hold
2,059
– – ﹤0.01% 3414
2019
Q1 		$8K Hold
2,059
– – ﹤0.01% 3273
2018
Q4 		$8K Hold
2,059
– – ﹤0.01% 3285
2018
Q3 		$18K Hold
2,059
– – ﹤0.01% 3233
2018
Q2 		$23K Buy
2,059
+864
+72% +$9.64K ﹤0.01% 3126
2018
Q1 		$14K Hold
1,195
– – ﹤0.01% 3170
2017
Q4 		$12K Sell
1,195
-851
-42% -$10.9K ﹤0.01% 3217
2017
Q3 		$33K Buy
2,046
+1,292
+171% +$17.9K ﹤0.01% 3037
2017
Q2 		$9K Hold
754
– – ﹤0.01% 3325
2017
Q1 		$16K Hold
754
– – ﹤0.01% 3125
2016
Q4 		$11K Buy
+754
New +$11.5K ﹤0.01% 3203

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Legal & General Group's CRVS Position: Q1 2026 in Review

Legal & General Group reduced its Corvus Pharmaceuticals (CRVS) stake by 1.9% in Q1 2026, selling an estimated $1.74K and leaving 5,678 shares worth $83.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2626.

Legal & General Group first reported a position in CRVS in Q4 2016 and has held it in 15 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Legal & General Group held 5,678 shares of Corvus Pharmaceuticals worth $83.1K as of Q1 2026.
  • Legal & General Group sold 109 Corvus Pharmaceuticals shares in Q1 2026, an estimated $1.74K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2626 holding.
  • Legal & General Group first reported a position in Corvus Pharmaceuticals in Q4 2016 and has held it in 15 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.